Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Enzymotec (ENZY): Julian Robertson’s Tiger Management Dumps Half of Its Stake

Page 1 of 12

Julian Robertson‘s Tiger Management has reported a large reduction in its holding of Enzymotec Ltd (NASDAQ:ENZY) in an amended filing with the Securities and Exchange Commission. Whereas the fund held more than 1.14 million shares of Enzymotec at the end of the first quarter, it now holds just 577,407 shares, which account for roughly 2.5% of the company’s common stock.

Julian Robertson

A biotechnology company based in Israel, Enzymotec Ltd (NASDAQ:ENZY) is a manufacturer and global distributor of bio-functional lipid ingredients and final products. So far this year, the stock has not been in a clear trend but has still managed to depreciate by roughly 8.6%. Shares are currently trading at a trailing Price to Earnings (P/E) ratio of 31, significantly lower than the industry average of 166, as reported by Yahoo! Finance. Enzymotec reported first quarter results on May 19, surpassing Wall Street’s expectations. Revenues came in at $14 million and the company registered adjusted earnings of $0.09 per share, topping analysts’ estimates of $0.05 per share.

At the end of the first quarter, approximately 35% of Enzymotec Ltd (NASDAQ:ENZY)’s outstanding stock was held by 6 elite hedge funds, unchanged during the quarter. Billionaire John Paulson is also betting on this stock, with his fund, Paulson & Co, having reported ownership of 4.22 million shares in its latest 13F filing. Jacob Gottlieb‘s Visium Asset Management also has Enzymotec in its equity portfolio, holding exactly 2.2 million shares according to its most recent 13F filing.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Tiger Partners Trading 0 577,407 0 577,407 577,407 2.5%
Tiger Partners 0 577,407 0 577,407 577,407 2.5%
Tiger Partners GP 0 577,407 0 577,407 577,407 2.5%
Tiger Management 0 577,407 0 577,407 577,407 2.5%
The Julian H. Robertson, Jr. Revocable Trust 0 577,407 0 577,407 577,407 2.5%
Julian H. Robertson, Jr 0 577,407 0 577,407 577,407 2.5%
Julian Robertson
Julian Robertson
Tiger Management

Page 1 of 12 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Enzymotec Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS 0.01 per share
(Title of Class of Securities)
M4059L101
(CUSIP Number)
July 1, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_]  Rule 13d-1(b)
[X]  Rule 13d-1(c)
[_]  Rule 13d-1(d)
__________
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Enzymotec Ltd.
Trade () Now!
Page 1 of 12

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!